You are here: Industry Insights > SARS-CoV-2

News List

UK scientists believe it is 'almost certain' a coronavirus variant will emerge that beats current vaccines firstwordpharma
August 02, 2021
An analysis published by the UK government's Scientific Advisory Group for Emergencies (SAGE) says they believe it is "almost certain" that a SARS-Cov-2 variant will emerge that "leads to current vaccine failure," CNN reported Sunday.
Rho Granted Extension by NIAID to Study Rate of COVID-19 Infection in US Children americanpharmaceuticalreview
July 30, 2021
Rho announced its Human Epidemiology and Response to SARS-CoV-2 (HEROS) study, to help determine the rate of the new coronavirus infection in children and their families in the U.S. has been extended through April 2022.
Vaxzevria is Highly Effective After One Dose Against Severe Disease or Hospitalisation Caused by Beta and Delta Variants of Concern drugs
July 30, 2021
Real-world data from Canada showed 82% and 87% effectiveness after one dose against hospitalisation or death caused by Beta/Gamma and Delta variants respectively.
COVID-19 Associated With Long-Term Cognitive Dysfunction, Acceleration Of Alzheimer's Symptoms firstwordpharma
July 30, 2021
Much has been learned about SARS-CoV-2, the virus that causes the novel coronavirus, since the beginning of the COVID-19 pandemic. However, questions remain about the long-term impact of the virus on our bodies and brains.
What a Post-Pandemic Advertising Market Looks Like prnewswire
July 30, 2021
From Main Street to Wall Street, the COVID-19 pandemic shook up the world, and the reverberations are still echoing. High-flying growth stocks related to software and cloud communications have cooled down since late in 2020 as people return to offices.
GSK and Vir enter supply deal with European Commission for Covid-19 drug pharmaceutical-technology
July 29, 2021
GlaxoSmithKline and Vir Biotechnology have entered a joint procurement agreement with the European Commission (EC) to deliver up to 220,000 doses of the companies’ experimental drug, sotrovimab, to treat Covid-19.
VIRALEZE SPL7013 virucidal (>99.99%) against Delta variant prnasia
July 28, 2021
Starpharma announced new data demonstrating that SPL7013, the antiviral agent in VIRALEZE™ nasal spray, is active against the highly transmissible Delta variant of SARS-CoV-2, achieving more than 99.99% reduction of infectious virus in ...
Advantages of intranasal vaccination against SARS-CoV-2 worldpharmanews
July 27, 2021
There are many reasons that an intranasal vaccine against the SARS-CoV-2 virus would be helpful in the fight against COVID-19 infections, University of Alabama at Birmingham immunologists Fran Lund, Ph.D., and Troy Randall, Ph.D., write in a viewpoint ...
EMA committee recommends Moderna’s Covid-19 vaccine for adolescents pharmaceutical-technology
July 27, 2021
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the marketing authorisation of the Moderna Covid-19 vaccine, Spikevax, for adolescents aged 12 to 17 years.
Antengene and Its Partners Publish Preclinical Data Demonstrating the Encouraging Activity of Selinexor in the Prevention and Treatment of SARS-CoV-2 Infections prnasia
July 26, 2021
In June 2021, results from a preclinical study jointly conducted by Antengene, American biopharmaceutical company Karyopharm Therapeutics and University of Georgia College of Veterinary Medicine has been published in a paper titled "selinexor ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 61 62 Next page